| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.19▲ | 1.20▲ | 1.19▲ | 1.18▲ | 1.22▲ |
| MA10 | 1.19▲ | 1.19▲ | 1.19▲ | 1.18▲ | 1.21▲ |
| MA20 | 1.20▲ | 1.21▲ | 1.22▼ | 1.26▼ | 1.31▼ |
| MA50 | 1.24▼ | 1.29▼ | 1.31▼ | 1.24▼ | 1.37▼ |
| MA100 | 1.33▼ | 1.28▼ | 1.26▼ | 1.34▼ | 1.60▼ |
| MA200 | 1.25▼ | 1.32▼ | 1.34▼ | 1.44▼ | 2.60▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.005▲ | 0.004▲ | -0.004▼ | -0.010▼ |
| RSI | 49.227▼ | 47.536▼ | 46.757▼ | 48.762▼ | 46.006▼ |
| STOCH | 70.513 | 64.642 | 62.213 | 38.082 | 31.986 |
| WILL %R | -7.692▲ | -36.842 | -36.842 | -58.621 | -74.627 |
| CCI | 97.134 | 44.200 | 46.394 | 1.782 | -48.361 |
| MA | $MRKR Price Crossed Above MA(13) | Set Alert |
|
Tuesday, September 22, 2026 05:14 AM
Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an ...
|
|
Tuesday, September 22, 2026 01:00 AM
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid ...
|
|
Tuesday, September 22, 2026 12:57 AM
Merck received FDA approval for a WINREVAIR label update based on Phase 3 HYPERION data showing reduced PAH clinical worsening events.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/09/26 | 1.18 | 1.235 | 1.18 | 1.22 | 38,706 |
| 21/09/26 | 1.18 | 1.22 | 1.18 | 1.20 | 24,232 |
| 18/09/26 | 1.19 | 1.23 | 1.17 | 1.18 | 47,300 |
| 17/09/26 | 1.13 | 1.225 | 1.13 | 1.18 | 60,596 |
| 16/09/26 | 1.17 | 1.18 | 1.13 | 1.14 | 35,900 |
| 15/09/26 | 1.17 | 1.23 | 1.15 | 1.17 | 11,899 |
| 14/09/26 | 1.16 | 1.2302 | 1.16 | 1.17 | 17,380 |
| 11/09/26 | 1.20 | 1.245 | 1.10 | 1.15 | 59,368 |
| 10/09/26 | 1.21 | 1.23 | 1.18 | 1.20 | 55,516 |
| 09/09/26 | 1.29 | 1.29 | 1.21 | 1.21 | 71,159 |
|
|
||||
|
|
||||
|
|